Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegilalide
- Development stage
- Phase 4
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tegilalide (SHR0410) is a selective **kappa opioid receptor (KOR) agonist** developed by **Jiangsu Hengrui Pharmaceuticals**. It is designed to provide potent analgesia while minimizing the side effects typically associated with mu-opioid receptor agonists, such as respiratory depression, gastrointestinal dysfunction, and potential for abuse. In June 2024, tegilalide received approval from the China National Medical Products Administration (NMPA) for the management of moderate to severe **postoperative pain** following abdominal surgery. The drug is administered intravenously and is currently being investigated in Phase 4 clinical trials for additional applications, including pain management during hysteroscopic procedures under non-intubation anesthesia. It is also in late-stage development for the treatment of **uremic pruritus** in patients undergoing hemodialysis.
- Brand names
- Ruibeian瑞倍安
- Other names
- tegilalide特吉拉利
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on tegilalide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegilalide.